Automating Wilson Wolf's G-Rex® bioreactors with Multiply Labs' robotic technology is driven by a mutual goal to standardize, simplify, and reduce costs for cell and gene-modified therapy manufacturing

Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf, an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex® bioreactors.

This collaboration is intended to provide the CGT field with easy-to-use high throughput ballroom manufacturing that reduces the need for highly skilled labor. The ultimate goal is to lower the barriers to widespread accessibility of potentially lifesaving cell and gene therapy drug products.

G-Rex® closed system bioreactors simplify CGT manufacturing by providing cells with unlimited oxygen and nutrients on demand. Without the need for media or oxygen pumps, G-Rex® bioreactors function as an all-in-one stand-alone activation, transduction, expansion, and concentration device. This unique attribute is ideal for high throughput automated movement of G-Rex® bioreactors in a ballroom setting and for standardizing much of the CGT manufacturing process.

“With G-Rex® making several commercial drug products, producing cells for nearly 50% of CGT clinical trials, and now becoming widely accepted as an all-in-one device, it’s time to apply automation selectively and thoughtfully. Automation doesn’t need to be complicated or unique to the field of cell and gene therapy. The simplicity of G-Rex® allows us to implement the type of automation solutions that occur millions of times a day in a wide variety of mature industries,” said John Wilson, CEO of Wilson Wolf Corporation. "Multiply Labs has been working independently with G-Rex® for several years and has exceptional experience in automation, so collaborating on our mutual goal of further cost reducing, simplifying, and standardizing CGT manufacturing is a good way to gain additional traction.”

"Our ongoing objective is to develop a seamlessly automated, plug-and-play solution for cell therapy manufacturing automation, aiming to lower labor costs, enhance output, and expand access of these critical therapies to a greater number of patients than ever before," said Fred Parietti, Ph.D., Co-Founder and CEO of Multiply Labs. "Our partnership with Wilson Wolf will be pivotal in realizing this future, as their G-Rex® bioreactors are extensively used for cell therapy manufacturing today. This means manufacturers can use the automated G-Rex® bioreactor without substantially changing their existing process."

Cytotherapy, the journal of the International Society for Cell & Gene Therapy (ISCT), recently published a first-of-its-kind peer-reviewed article on Multiply Labs’ proof-of-concept robotic system developed with leading cell therapy organizations. It found that Multiply Labs’ robotic system can automate T cell-based therapy expansion without compromising critical process parameters. Industry estimates suggest this technology could cut typical GMP-level cell therapy manufacturing costs by around 70% per product.

About Multiply Labs

Multiply Labs is a robotics company that provides autonomous manufacturing technology to the pharmaceutical industry. The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space. Multiply Labs’ expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, electrical engineers, computer scientists, software engineers and pharmaceutical scientists. The founding team got in touch because of their shared love of robots at MIT. The company is based in San Francisco, California. For more information, please visit www.multiplylabs.com.

About Wilson Wolf Corporation

Wilson Wolf Corporation (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.

Wilson Wolf’s mission is to create hope for cancer patients, one G-Rex® device at a time.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240502701121/en/